Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VG201 is a first-in-class oncolytic HSV-1 virus that has enhanced oncolytic activity specifically for tumors expressing carcinoembryonic antigen (CEA) and is designed to produce immune-stimulating cytokines IL-12 and IL-15/IL15Rα.
Lead Product(s): VG201
Therapeutic Area: Oncology Product Name: VG201
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 08, 2022